GenVec, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
32 Pages - GMD12104
$1,500.00

Summary

Global Markets Direct’s, ‘GenVec, Inc. - Product Pipeline Review - 2014’, provides an overview of the GenVec, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GenVec, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GenVec, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GenVec, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GenVec, Inc.’s pipeline products

Reasons to buy

- Evaluate GenVec, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GenVec, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GenVec, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GenVec, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GenVec, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GenVec, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
GenVec, Inc. Snapshot 4
GenVec, Inc. Overview 4
Key Information 4
Key Facts 4
GenVec, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
GenVec, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
GenVec, Inc. - Pipeline Products Glance 11
GenVec, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
GenVec, Inc. - Early Stage Pipeline Products 12
IND/CTA Filed Products/Combination Treatment Modalities 12
Preclinical Products/Combination Treatment Modalities 13
GenVec, Inc. - Drug Profiles 14
TNFerade 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CGF-166 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
GV-2207 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
GV-2311 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
GenVec, Inc. - Pipeline Analysis 19
GenVec, Inc. - Pipeline Products by Target 19
GenVec, Inc. - Pipeline Products by Route of Administration 20
GenVec, Inc. - Pipeline Products by Molecule Type 21
GenVec, Inc. - Pipeline Products by Mechanism of Action 22
GenVec, Inc. - Recent Pipeline Updates 23
GenVec, Inc. - Dormant Projects 24
GenVec, Inc. - Company Statement 25
GenVec, Inc. - Locations And Subsidiaries 30
Head Office 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
GenVec, Inc., Key Information 4
GenVec, Inc., Key Facts 4
GenVec, Inc. - Pipeline by Indication, 2014 6
GenVec, Inc. - Pipeline by Stage of Development, 2014 7
GenVec, Inc. - Monotherapy Products in Pipeline, 2014 8
GenVec, Inc. - Partnered Products in Pipeline, 2014 9
GenVec, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 10
GenVec, Inc. - Phase I, 2014 11
GenVec, Inc. - IND/CTA Filed, 2014 12
GenVec, Inc. - Preclinical, 2014 13
GenVec, Inc. - Pipeline by Target, 2014 19
GenVec, Inc. - Pipeline by Route of Administration, 2014 20
GenVec, Inc. - Pipeline by Molecule Type, 2014 21
GenVec, Inc. - Pipeline Products by Mechanism of Action, 2014 22
GenVec, Inc. - Recent Pipeline Updates, 2014 23
GenVec, Inc. - Dormant Developmental Projects,2014 24

List of Figures
GenVec, Inc. - Pipeline by Top 10 Indication, 2014 6
GenVec, Inc. - Pipeline by Stage of Development, 2014 7
GenVec, Inc. - Monotherapy Products in Pipeline, 2014 8
GenVec, Inc. - Pipeline by Top 10 Molecule Type, 2014 21

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax